TSVT NASDAQ
2seventy bio, Inc.
1W: +0.0%
1M: +0.8%
3M: +104.1%
1Y: +11.6%
3Y: -64.3%
$5.00
Last traded 2025-05-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$266.1M
52W Range2.29-5.3
Volume1,158,184
Avg Volume1,462,258
Beta1.05
Dividend—
Analyst Ratings
Company Info
CEOWilliam D. Baird III,
Employees65
SectorHealthcare
IndustryBiotechnology
IPO Date2021-11-03
Website2seventybio.com
60 Binney Street
Cambridge, MA 02142
US
Cambridge, MA 02142
US
339 499 9300
About 2seventy bio, Inc.
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Glickman Sarah JS | D-Return | 12,050 | — | 2025-05-13 |
| Glickman Sarah JS | D-Return | 24,100 | $3.93 | 2025-05-13 |
| Glickman Sarah JS | U-Tender | 15,602 | — | 2025-05-13 |
| Casdin Capital, LLC | U-Tender | 2,000,000 | $5.00 | 2025-05-13 |
| Casdin Capital, LLC | D-Return | 33,400 | $4.54 | 2025-05-13 |